Axxam enters CNS partnership with Lundbeck
for Lead Identification
 

The signature of this first partnership agreement between Axxam and Lundbeck, for the identification and qualification of small molecules relevant to CNS targets, comes after more than five years of successful collaboration in assay development and High-Throughput Screening.  The partnership relies on Axxam’s science-driven approach to deliver qualified hits and leads, also for complex targets, through an optimized and elaborated screening funnel involving a panel of experts in the fields, including but not limited to automation, cell biology, electrophysiology, HTS, imaging, and compound profiling. Furthermore, within this partnership, Lundbeck will also have access to Axxam’s prestigious compound collection AXXDiversity composed of over 345.000 carefully selected compounds.